Pharmacovigilance Market (By Service Provider: In-house, Contract Outsourcing; By Product Life Cycle: Pre-clinical, Phase I, Phase II, Phase III, Phase IV; By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining; By Process Flow: Case Data Management, Signal Detection, Risk Management System) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20222030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Pharmacovigilance Market, By Service Provider

7.1.  Pharmacovigilance Market, by Service Provider, 2021-2030

7.1.1.    In-house

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Contract Outsourcing

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Pharmacovigilance Market, By Product Life Cycle

8.1.  Pharmacovigilance Market, by Product Life Cycle, 2021-2030

8.1.1.    Pre-clinical

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Phase I

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Phase II

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Phase III

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Phase IV

8.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Pharmacovigilance Market, By Type

9.1.  Pharmacovigilance Market, by Type, 2021-2030

9.1.1.    Spontaneous Reporting

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Intensified ADR Reporting

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Targeted Spontaneous Reporting

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Cohort Event Monitoring

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    EHR Mining

9.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Pharmacovigilance Market, By Process Flow

10.1.        Pharmacovigilance Market, by Process Flow, 2021-2030

10.1.1.  Case Data Management

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Signal Detection

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Risk Management System

10.1.3.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Pharmacovigilance Market, By Therapeutic Area

11.1.        Pharmacovigilance Market, by Therapeutic Area, 2021-2030

11.1.1.  Oncology

11.1.1.1.      Market Revenue and Forecast (2017-2030)

11.1.2.  Neurology

11.1.2.1.      Market Revenue and Forecast (2017-2030)

11.1.3.  Cardiology

11.1.3.1.      Market Revenue and Forecast (2017-2030)

11.1.4.  Respiratory Systems

11.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 12.      Global Pharmacovigilance Market, By End-use

12.1.        Pharmacovigilance Market, by End-use, 2021-2030

12.1.1.  Pharmaceuticals

12.1.1.1.      Market Revenue and Forecast (2017-2030)

12.1.2.  Biotechnology Companies

12.1.2.1.      Market Revenue and Forecast (2017-2030)

12.1.3.  Medical Device Manufacturers

12.1.3.1.      Market Revenue and Forecast (2017-2030)

12.1.4.  Others

12.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 13.      Global Pharmacovigilance  Market, Regional Estimates and Trend Forecast

13.1.        North America

13.1.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.1.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.1.3.  Market Revenue and Forecast, by Type (2017-2030)

13.1.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.1.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.1.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.1.7.  U.S.

13.1.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.1.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.1.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.1.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.1.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.1.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.1.8.  Rest of North America

13.1.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.1.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.1.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.1.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.1.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.1.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.        Europe

13.2.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.3.  Market Revenue and Forecast, by Type (2017-2030)

13.2.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.2.7.  UK

13.2.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.2.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.8.  Germany

13.2.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.2.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.9.  France

13.2.9.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.9.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.9.3.      Market Revenue and Forecast, by Type (2017-2030)

13.2.9.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.9.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.9.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.2.10.               Rest of Europe

13.2.10.1.   Market Revenue and Forecast, by Service Provider (2017-2030)

13.2.10.2.   Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.2.10.3.   Market Revenue and Forecast, by Type (2017-2030)

13.2.10.4.   Market Revenue and Forecast, by Process Flow (2017-2030)

13.2.10.5.   Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.2.10.6.   Market Revenue and Forecast, by End-use (2017-2030)

13.3.        APAC

13.3.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.3.  Market Revenue and Forecast, by Type (2017-2030)

13.3.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.3.7.  India

13.3.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.3.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.3.8.  China

13.3.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.3.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.3.9.  Japan

13.3.9.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.9.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.9.3.      Market Revenue and Forecast, by Type (2017-2030)

13.3.9.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.9.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.9.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.3.10.               Rest of APAC

13.3.10.1.   Market Revenue and Forecast, by Service Provider (2017-2030)

13.3.10.2.   Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.3.10.3.   Market Revenue and Forecast, by Type (2017-2030)

13.3.10.4.   Market Revenue and Forecast, by Process Flow (2017-2030)

13.3.10.5.   Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.3.10.6.   Market Revenue and Forecast, by End-use (2017-2030)

13.4.        MEA

13.4.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.3.  Market Revenue and Forecast, by Type (2017-2030)

13.4.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.4.7.  GCC

13.4.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.4.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.4.8.  North Africa

13.4.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.4.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.4.9.  South Africa

13.4.9.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.9.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.9.3.      Market Revenue and Forecast, by Type (2017-2030)

13.4.9.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.9.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.9.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.4.10.               Rest of MEA

13.4.10.1.   Market Revenue and Forecast, by Service Provider (2017-2030)

13.4.10.2.   Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.4.10.3.   Market Revenue and Forecast, by Type (2017-2030)

13.4.10.4.   Market Revenue and Forecast, by Process Flow (2017-2030)

13.4.10.5.   Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.4.10.6.   Market Revenue and Forecast, by End-use (2017-2030)

13.5.        Latin America

13.5.1.  Market Revenue and Forecast, by Service Provider (2017-2030)

13.5.2.  Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.5.3.  Market Revenue and Forecast, by Type (2017-2030)

13.5.4.  Market Revenue and Forecast, by Process Flow (2017-2030)

13.5.5.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.5.6.  Market Revenue and Forecast, by End-use (2017-2030)

13.5.7.  Brazil

13.5.7.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.5.7.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.5.7.3.      Market Revenue and Forecast, by Type (2017-2030)

13.5.7.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.5.7.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.5.7.6.      Market Revenue and Forecast, by End-use (2017-2030)

13.5.8.  Rest of LATAM

13.5.8.1.      Market Revenue and Forecast, by Service Provider (2017-2030)

13.5.8.2.      Market Revenue and Forecast, by Product Life Cycle (2017-2030)

13.5.8.3.      Market Revenue and Forecast, by Type (2017-2030)

13.5.8.4.      Market Revenue and Forecast, by Process Flow (2017-2030)

13.5.8.5.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

13.5.8.6.      Market Revenue and Forecast, by End-use (2017-2030)

Chapter 14.  Company Profiles

14.1.              Accenture

14.1.1.  Company Overview

14.1.2.  Product Offerings

14.1.3.  Financial Performance

14.1.4.  Recent Initiatives

14.2.              Linical Accelovance

14.2.1.  Company Overview

14.2.2.  Product Offerings

14.2.3.  Financial Performance

14.2.4.  Recent Initiatives

14.3.              Cognizant

14.3.1.  Company Overview

14.3.2.  Product Offerings

14.3.3.  Financial Performance

14.3.4.  Recent Initiatives

14.4.              Laboratory Corporation of America Holdings

14.4.1.  Company Overview

14.4.2.  Product Offerings

14.4.3.  Financial Performance

14.4.4.  Recent Initiatives

14.5.              IBM Corporation

14.5.1.  Company Overview

14.5.2.  Product Offerings

14.5.3.  Financial Performance

14.5.4.  Recent Initiatives

14.6.              ArisGlobal

14.6.1.  Company Overview

14.6.2.  Product Offerings

14.6.3.  Financial Performance

14.6.4.  Recent Initiatives

14.7.              ICON plc.

14.7.1.  Company Overview

14.7.2.  Product Offerings

14.7.3.  Financial Performance

14.7.4.  Recent Initiatives

14.8.              Capgemini

14.8.1.  Company Overview

14.8.2.  Product Offerings

14.8.3.  Financial Performance

14.8.4.  Recent Initiatives

14.9.              ITClinical

14.9.1.  Company Overview

14.9.2.  Product Offerings

14.9.3.  Financial Performance

14.9.4.  Recent Initiatives

14.10.           FMD K&L

14.10.1.               Company Overview

14.10.2.               Product Offerings

14.10.3.               Financial Performance

14.10.4.               Recent Initiatives

Chapter 15.  Research Methodology

15.1.              Primary Research

15.2.              Secondary Research

15.3.              Assumptions

Chapter 16.  Appendix

16.1.              About Us

Glossary of Terms